170 related articles for article (PubMed ID: 15988143)
21. What signals are generated by anti-CD20 antibody therapy?
Bonavida B
Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-148b enhances the radiosensitivity of non-Hodgkin's Lymphoma cells by promoting radiation-induced apoptosis.
Wu Y; Liu GL; Liu SH; Wang CX; Xu YL; Ying Y; Mao P
J Radiat Res; 2012 Jul; 53(4):516-25. PubMed ID: 22843616
[TBL] [Abstract][Full Text] [Related]
23. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
24. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
25. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
Zhang N; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
[TBL] [Abstract][Full Text] [Related]
26. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
27. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
Alas S; Ng CP; Bonavida B
Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
[TBL] [Abstract][Full Text] [Related]
28. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
29. Camptothecin enhances
Kumar C; Sharma R; Repaka KM; Pareri AU; Dash A
J Cancer Res Ther; 2021; 17(4):943-950. PubMed ID: 34528546
[TBL] [Abstract][Full Text] [Related]
30. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
31. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
An S; Yap D; Knox KA
Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Reddy N; Holkova B; Ottman E; Czuczman MS
Clin Cancer Res; 2005 Aug; 11(16):5984-92. PubMed ID: 16115943
[TBL] [Abstract][Full Text] [Related]
33.
Malenge MM; Patzke S; Ree AH; Stokke T; Ceuppens P; Middleton B; Dahle J; Repetto-Llamazares AHV
J Nucl Med; 2020 Oct; 61(10):1468-1475. PubMed ID: 32245896
[TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab.
Kapadia NS; Engles JM; Wahl RL
J Nucl Med; 2008 Apr; 49(4):674-8. PubMed ID: 18344431
[TBL] [Abstract][Full Text] [Related]
35. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
37. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
38. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
Buhé V; Guerrier T; Youinou P; Berthou C; Loisel S
Ann N Y Acad Sci; 2009 Sep; 1173():858-64. PubMed ID: 19758238
[TBL] [Abstract][Full Text] [Related]
39. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
[TBL] [Abstract][Full Text] [Related]
40. CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.
Matou-Nasri S; Rabhan Z; Al-Baijan H; Al-Eidi H; Yahya WB; Al Abdulrahman A; Almobadel N; Alsubeai M; Al Ghamdi S; Alaskar A; AlBalwi M; Alzahrani M; Alabdulkareem I
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):239-252. PubMed ID: 27641442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]